Overview

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Status:
RECRUITING
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Novartis Pharmaceuticals
Treatments:
asciminib
blinatumomab